API | uprifosbuvir

uprifosbuvir Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. As of 2019 it was in Phase III human clinical trials. ^Wikipedia

Chemistry

SMILES: CC(C)OC(=O)[C@@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1
InChIKey: SFPFZQKYPOWCSI-KHFYHRBSSA-N
Mol. Mass: 545.91
ALogP: 1.93 Partition coefficient
ChEMBL Molecule:
uprifosbuvir

More Chemistry

Pharmacology

Mechanisms of Action:
- Genome polyprotein (Hepatitis C virus genotype 1b (strain HC-J4) (HCV)) ^UniProt
- RNA-directed RNA polymerase (Hepatitis C virus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Yes

mk-3682 | uprifosbuvir

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Digestive System Diseases (Phase 2)

Flaviviridae Infections (Phase 2)

Hepatitis (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Viral, Human (Phase 2)

Liver Diseases (Phase 2)

RNA Virus Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue